ESTRO 2025 - Abstract Book

S83

Invited Speaker

ESTRO 2025

In an increasingly automated environment with rapidly developing technology and techniques the roles and responsibilities are changing radically with a greater emphasis on the evaluation of technical factors and patient clinical status and making a decision on the ‘plan of the day’ based on the findings. Individualisation of patient treatment approaches, moving away from routine techniques where all patients receive a standard prescription, requires greater awareness and flexibility which must be based on specialist knowledge and competences to ensure quality and safety throughout the patient pathway. Devolution of responsibility and shared decision making are increasingly the ‘norm’. Evolving roles and responsibilities and the devolution of responsibility impacts on all team members and necessitates a different approach to education content. In addition we are working in an increasingly automated environment with greater reliance on information technology and less transparency. Education programmes must enable all professionals to interrogate the data produced in order to make decisions in order to offer the highest quality and safety to patients in their care.

4778

Speaker Abstracts Implementing new technology: Proactive risk management and regulatory compliance Jonathan Berthold

OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. Center for Advanced Systems Understanding, CASUS, Görlitz, Germany. Helmholtz-Zentrum Dresden-Rossendorf, CASUS - Center for Advanced Systems Understanding, Dresden, Germany Abstract: Translational research is key to implementing new technologies into radiation therapy. However, bringing an application to the patient has to follow some regulatory requirements. Since 2021, manufactures of medical products are obligated to comply with the medical device regulation (MDR, 2017/745) of the European Union. The regulation includes in-house developments by clinical research centers, many of which are unsure how to deal with this new situation. This presentation shall give an overview of important aspects of MDR requirements from a researcher’s point of view. A more detailed look shall be taken on risk management in the context of MDR. Lastly, experiences and lessons learned from the ongoing implementation of a treatment verification system for proton therapy shall be shared. While implementing new technologies is a tedious process, it is always good to remember that patients will directly benefit from our common efforts.

4779

Speaker Abstracts EGFR-driven NSCLC and radiotherapy - pro Dirk De Ruysscher Radiation Oncology, Maastro, Maastricht, Netherlands

Abstract:

EGFR inhibitors such as osimertinib lead to an impressive improvement of DFS/ PFS in all stages of NSCLC and both for control of the primary tumor, lymph node and distant metastases. But how to combine with radiotherapy?